Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2023 Jul 15;13:11453. doi: 10.1038/s41598-023-37846-y

Altered neutrophil-to-lymphocyte ratio in patients with non-affective first episode psychosis and its relationship with symptom severity and cognitive impairment

Kwan Keung Leung 1,2, Yip Chau Wong 1,2, Ka Sin Shea 1,2, Sheung Chun Chan 1,2, Wing Chung Chang 4, Yi Man Flora Mo 1,2, Sau Man Sandra Chan 1,2,3,
PMCID: PMC10349799  PMID: 37454218

Abstract

Signatures of immune dysregulation as clinical biomarker for psychosis have remained unclear. We aimed to compare the Neutrophil-to-lymphocyte ratio (NLR) of patients with acute non-affective first-episode psychosis (FEP) with healthy controls after accounting for emotional states. We also explored the associations of NLR with symptom severity, onset profile and cognitive functions. The NLR was enumerated from complete blood count taken within a week of assessment. All FEP patients were rated on the Positive and Negative Syndrome Scale (PANSS) and the Clinician Global Impression-Severity (CGI-S) with verbal memory and executive functions assessed with the Cambridge Neuropsychological Test Automated Battery. Prevailing emotional state was measured with Beck Depression Inventory-II and Beck Anxiety Inventory. Out of seventy-nine consecutive FEP patients presenting to the study site, twenty-seven subjects were eligible and recruited. Twenty-seven age-/sex-matched controls were recruited. FEP patients had an NLR of 1.886 over the controls after accounting for scores on emotional states. The NLR of FEP patients was positively associated with CGI-S scores, PANSS positive symptom, disorganization and excitation scores. There was no significant correlation between NLR with the duration of untreated psychosis and cognitive performances. These findings support using NLR as a clinical biomarker in FEP, purporting further prospective study to measure NLR changes in the course of treatment.

Subject terms: Inflammation, Predictive markers

Introduction

Inflammation and immune dysregulation have been implicated in the pathogenesis of major neuropsychiatric disorders, including mood or anxiety-related disorders1 and psychosis25. Alterations in circulating blood cytokine network were reported6. Abnormal immune cell counts have been reported in patients with schizophrenia and those with first-episode psychosis (FEP)79. Some studies revealed upregulation of pro-inflammatory cytokines10 and high sensitivity C-reactive protein (CRP)11 in psychosis. A recent meta-analysis also confirmed an imbalance of pro-inflammatory status and a reduction of anti-oxidant signals in patients with FEP compared with healthy controls12. Treatment with antipsychotics was shown to modulate the inflammatory status in patients with psychosis, although the effects were inconsistent across different psychotropics13. Other studies revealed differential immune status with levels of psychotic symptom severity14, and among antipsychotic responders or non-responders in FEP15. Symptoms aside, alterations of immune status were associated with abnormal cognitive functions in schizophrenia, as reported in a recent systematic review and meta-analysis. However, the associations found in these studies were weak, given the small effect size of the correlations reported16,17. Specific profiles of inflammatory biomarkers were reported to correlate with some cognitive domains in FEP patients18.

Routine serum assays of inflammatory biomarkers are often unavailable in psychiatric clinical settings. On the other hand, neutrophil-to-lymphocyte ratio (NLR) is a clinically accessible candidate biomarker easily enumerated from complete blood count (CBC) measured in routine clinical care. A ratio between the neutrophil and lymphocyte count conjugates innate and adaptive immunity. An increase in neutrophil levels could reflect an elevated systemic inflammatory status augmenting neutrophil-mediated killing with adaptive regulatory immunity in various diseases19. NLR has been reported as a prognostic indicator in disease entities like cancer20, metabolic syndrome21, sepsis22, and inflammatory bowel diseases23. A recent cross-sectional study revealed an increased NLR in more than 13,000 clinically diverse service users attending a regional psychiatric service in South London. Such transdiagnostic association in psychiatric service users was also influenced by age (positive correlation), psychotropics, and ethnicity (white over non-white) relative to the profiles of healthy controls (n > 3000) drawn from a National Health Survey24. Another recent meta-analysis pooling data from retrospective or cross-sectional studies showed an elevated NLR in patients with psychosis over healthy controls25. Emerging evidence supports a possible association of NLR with positive psychotic symptoms in schizophrenia26 and a positive association of higher NLR with the severity of psychotic symptoms in unmedicated patients with schizophrenia27. However, the results of these studies could not discriminate between clinically remitted patients and those who were acutely psychotic.

In summary, there are main knowledge gaps in the understanding of clinical correlates of NLR in psychosis. First, existing case-controlled studies in patients with psychosis did not account for the emotional states of the patients with psychosis even though stress and emotion have complex interplay with inflammatory activity28. Given some earlier reports suggesting the association of altered NLR in mood disorders29, the emotional state is a potential confounder to be considered in the analysis of NLR in psychosis. Further, the evidence from a retrospective review of a multi-ethnic clinical registry suggested the role of ethnicity in moderating the association of NLR and psychiatric disorder in a UK cohort24, in which data on Chinese subjects were lacking. It also remains unclear whether NLR is a state or trait marker in psychosis, and notably, its linkage to symptom severity and cognitive impairment has remained obscure. Many studies included patients with a relapsing course of schizophrenia, in which long illness duration and chronic psychotropic treatment might confound the clinical association of the inflammatory status30. Data were lacking in patients with FEP, a relatively homogenous clinical population in terms of duration of illness and exposure to psychotropics.

This case–control study primarily aimed to compare the NLR of ethnic Chinese patients with non-affective FEP and the age-/sex-matched healthy controls. It also aimed to explore the association of NLR with severity of psychotic symptoms and cognitive function after accounting for current emotional states.

Methods

Participants and settings

The current study was approved by the Chinese University of Hong Kong (CUHK) – NTEC Clinical Research Ethics Committee (CREC reference number: 2020.250). We recruited consecutive patients ages 18–50 years with non-affective FEP from two clinical settings: 1) hospitalized patients presenting to a regional tertiary psychiatric inpatient unit (Tai Po Hospital, TPH) serving the New Territories East Cluster under the public sector; 2) those referred for assessment at the FEP clinic of Alice Ho Miu Ling Nethersole Hospital (AHNH). Based on a similar study design comparing the blood parameters of FEP subjects and healthy control 31, the mean NLR assumed was 2.7 in FEP patients and 1.6 in control, and a pooled standard deviation of 1.9 and 0.6, respectively. Taking the probability of type I error (α) as 0.05 and power level (1-β) as 80%, a sample size of 27 per group would be needed to adequately test for difference in the NLR between the subject group and healthy control. The research team posted an advertisement at TPH/AHNH in the same study period, when adult healthy volunteers signed up and were enrolled as control participants only if their age and gender matched the recruited cases with non-affective FEP. Non-affective FEP patients and control participants with informed consent were recruited and assessed from November 2020 to July 2021. Inclusion and exclusion criteria were summarized in Supplementary Table 1. The exclusion criteria were infections, systemic diseases and metabolic problems, recent traumas or injuries, pregnancies, recent blood donations or transfusions, smoking, recent flu or COVID-19 vaccines, any medication or supplement use that potentially affects inflammatory status25. Non-affective FEP patients were defined as having the first inpatient psychiatric hospitalization or outpatient FEP consultation while meeting the diagnostic criteria for schizophrenia spectrum disorder in the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV). All clinical diagnoses were confirmed with a validated Chinese-bilingual version of Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) 32. All research was performed in accordance with relevant guidelines and regulations.

Data collection and blood analysis

The demographic and clinical data of non-affective FEP subjects were collected from a direct interview supplemented with electronic clinical record review. The research interviews were conducted on FEP subjects within 1 week after presenting to the inpatient or outpatient unit. All blood samplings were done in the morning. The earliest available blood count values were used to minimize the potential effects of healthcare interventions. The same protocols for blood sampling and clinical interview were carried out for the healthy controls. The assessor was blinded to the blood parameters while performing all clinical interviews or assessments. All blood assays were processed in an accredited pathology laboratory in AHNH. The NLR of each participant was not analyzed until all clinical data were collected.

Clinical and cognitive assessments

Psychiatric disorders were diagnosed with a validated Chinese-bilingual version of DSM-IV SCID-I32. Non-affective psychosis was defined as those diagnosed with schizophrenia, schizophreniform disorder, delusional disorder, or psychotic disorder not otherwise specified. The psychotic symptoms of all FEP patients were assessed using the PANSS with precise ratings33,34. PANSS positive, disorganization, negative, excitation, anxiety and depressive symptom scores were derived from previous factor-analytic study on FEP patients35. The emotional states were assessed with validated Chinese versions of BDI-II and BAI36 to record the prevailing mood symptoms in the past week. The neurocognitive assessment was carried out by a computerized system known as the CANTAB37. An earlier systematic review reported verbal memory and executive functions were the domains with the largest effect size in cognitive impairment of FEP38. Verbal Recognition Memory (VRM) tests, Spatial Working Memory (SMW) tests, and the One-Touch Stockings of Cambridge (OTS) tests were selected to assess verbal memory, working memory and executive functions. CGI-S was used to gauge the global clinical severity39.

Statistical analysis

Power and sample size estimations were done using the computerized G-power analysis40. Statistical analyses were performed using the IBM Statistical Package for the Social Sciences for Windows Version 26.0 (IBM Corp., Armonk. NY, USA computer software). Descriptive statistics were used to summarize the demographic and clinical data. Continuous variables were expressed as means and standard deviations if the data were normally distributed, while median and interquartile ranges (IQR) if the data were not normally distributed. Categorical variables were presented as absolute numbers and proportions (percentages). A Kolmogorov–Smirnov test was used to examine each variable for normality. For comparing the sex- and age-matched subjects, continuous data were analyzed by paired t-test if the data were normally distributed. At the same time, Wilcoxon signed-rank test was used if the data were not normally distributed. Categorical data were analyzed by McNemar test (two categories only) and Marginal Homogeneity test (more than two categories). Spearman's rho correlation coefficient was used to investigate any significant relationship between two continuous variables. Generalized Estimating Equation (GEE) model was used in assessing the differences between the cases and controls by accounting for the working correlation matrix of putative confounders. The occupation status, years of education, BDI-II and BAI scores were included in the model for analyses. All tests were set with a significant level of p < 0.05.

Results

Characteristics of the sample

Consecutive FEP patients from November 2020 to July 2021 were screened for eligibility for the study as shown in Fig. 1. Seventy-nine patients were screened for eligibility. Forty-eight patients were excluded due to the conditions specified in the exclusion criteria. Among the thirty-one eligible patients, four refused to participate or failed to cooperate during the assessment. Twenty-seven patients were recruited, and twenty-six patients were hospitalized at recruitment. Age (+ /− 2 years)- and sex-matched healthy controls were enrolled in the same period through advertising. The demographic data and clinical parameters of the FEP patients and healthy controls are summarized in Table 1. The groups were comparable except in “years of education” and “occupation status”. The healthy controls had significantly higher years of education than the FEP patients, and all the healthy controls were employed at the time of the assessment. Twenty-seven FEP patients were respectively diagnosed with schizophrenia (n = 8), schizophreniform disorder (n = 4), psychosis not otherwise specified (NOS) (n = 12), and delusional disorder (n = 3).

Figure 1.

Figure 1

The study inclusion and exclusion process.

Table 1.

Demographic information and clinical parameters of both FEP patients and healthy control.

Variables of interest Level FEP Control p value
(n = 27) (n = 27)
Demographics
 Female gender, n (%) 18 (66.67) 18 (66.67) 1
 Age at entry, mean (SD) 30.56 (8.06) 31.15 (7.56) 0.065
 Years of education, mean (SD) 15.8 (3.96) 20.1 (1.85) * < 0.001
 Occupation, n (%) No 16 (59.26) 0 (0) * < 0.001
Yes 11 (40.74) 27 (100)
 Marital status, n (%) Single 17 (62.96) 18 (66.67) 0.206
Married 7 (25.93) 9 (33.33)
Divorced 3 (11.11) 0 (0)
 Number of cohabitants, mean (SD) 2.48 (1.42) 2.48 (1.37) 1
 Religion, n (%) No 21 (77.78) 22 (81.48) 1
Yes 6 (22.22) 5 (18.52)
 Smoking status, n (%) No 24 (88.89) 26 (96.3) 0.5
Yes (< 15 cig/day) 3 (11.11) 1 (3.7)
 Body mass index, mean (SD) 22.11 (4.22) 20.73 (2.24) 0.171
 Family history of psychosis, n (%) No 22 (81.48) 26 (96.3) 0.125
Yes 5 (18.52) 1 (3.7)
Psychiatric diagnosis, n (%)
 Schizophrenia 8 (29.63)
 Schizophreniform disorder 4 (14.81)
 Psychosis NOS 12 (44.44)
 Delusional disorder 3 (11.11)
Illness Characteristics
 Log DUPa, mean (SD) 0.837(0.646)
Use of antipsychotics on presentation, n (%) No 24 (88.89)
Yes (treatment ≤ 1 week) 3 (11.11)
Symptom and clinical severity
 PANSS-positive symptom score, mean (SD)b 27.4 (6.39)
 PANSS-disorganization score, mean (SD)b 25 (5.3)
 PANSS-negative symptom score, mean (SD)b 27 (6.75)
 PANSS-excitation score, mean (SD)b 13.1 (4.12)
 PANSS-anxiety and depressive symptom score, mean (SD)b 13.3 (4.12)
 CGI-S score, mean (SD) 5.37 (1.08)
Emotional states
 BDI-II, mean (SD) 13.1 4.67 * < 0.001
 BAI, mean (SD) 14.8 4.19 * < 0.001

SD, standard deviation; Psychosis NOS = Psychosis not otherwise specified; DUP, duration of untreated psychosis; PANSS, Positive and Negative Syndrome Scale; CGI-S, Clinical Global Impression-Severity; BDI-II, Beck Depression Inventory-II; BAI, Beck Anxiety Inventory.

*Denotes p < 0.05.

aDUP was log-transformed for parametric analysis due to its skewed distribution.

bPANSS positive, disorganization, negative, excitation, anxiety and depressive symptom scores were derived on the basis of a previous factor-analytic study on FEP patients35.

Significant values are in bold.

Comparison of NLR between FEP and control groups

Analyses of blood count parameters are summarized in Table 2. The FEP patients had a significantly higher total white cell count (p = 0.009) and neutrophil count (p < 0.001) but a significantly lower lymphocyte count (p = 0.002) than the healthy controls. There were no differences between the monocyte (p = 0.526) and platelet count (p = 0.469). The NLR was significantly higher in the FEP patients than the healthy controls (p < 0.001). All except three of the FEP patients were unmedicated. The medicated FEP patients had been prescribed the second-generation antipsychotics (2 with risperidone, 3- and 5-day treatment; 1 with olanzapine, 3-day treatment) within 1 week before hospitalization. A post-hoc analysis excluding the three medicated FEP patients found a significantly higher NLR in the FEP group than in the controls (p < 0.001). Excluding smokers in the analysis also yielded higher NLR in the FEP group than in the controls (p < 0.001).

Table 2.

The blood count parameters of both FEP patients and healthy control.

Variable FEP (n = 27) Control (n = 27) p-value
White cell count Median (IQR) 6.7 (5.5–7.8) 5.4 (4.7–7.3) *0.009
Neutrophil Median (IQR) 4.6 (3.6–5.6) 3.2 (2.6–4.1) * < 0.001
Lymphocyte Median (IQR) 1.3 (1–1.9) 1.7 (1.4–2) *0.002
Monocyte median (IQR) 0.5 (0.4–0.6) 0.5 (0.4–0.5) 0.526
Platelet Median (IQR) 242 (214–298) 255 (208–286) 0.469
NLR Median (IQR) 3.6 (2.29–4.31) 1.78 (1.49–2.14) * < 0.001
NLR (no antipsychotics, n = 24) Median (IQR) 3.6 (2.28–4.28) 1.79 (1.55–2.16) * < 0.001
NLR (non-smoker, n = 24)^ Median (IQR) 3.37 (2.28–4.22) 1.85 (1.47–2.09) * < 0.001

IQR, interquartile range; NLR, Neutrophil-to-Lymphocyte Ratio.

*Denotes p < 0.05.

^1 pair of age- and sex-matched FEP and control subjects were both smokers thus n = 24.

Significant values are in bold.

Scores on both BDI-II and BAI were found to be significantly higher in the FEP patients than in the healthy controls (both p < 0.001), reflecting the differences in the mood state of FEP patients in the week before the assessment (Table 1). To adjust for the confounding effects of the mood state, a GEE model was used in assessing the differences in NLR between FEP patients and healthy controls by accounting for the working correlation matrix. Years of education and occupation status as potential confounding factors were also included in the model, as they were found to be different between FEP and control group. Table 3 showed that the FEP group, with NLR as the outcome, had a higher score (β = 1.886, confidence interval 1.076–2.695, p < 0.001) over the controls after adjusting for the scores on BDI-II/BAI, years of education and occupation. The analysis suggested that the FEP case would have an NLR value 1.886 times higher than the healthy control group after accounting for the differences in emotional state, years of education, and occupation status. Repeating the analyses excluding the three medicated FEP patients and their respective matched controls yielded a higher NLR in the FEP patients than in healthy controls (data not shown). As there was ample evidence that the body mass index (BMI) could affect inflammatory status, and hence NLR41, we also analyzed BMI as a potential covariate, even though the BMIs were comparable between the two groups. We found that the NLR of FEP subjects was still higher than the controls after accounting for BMIs (β = 1.641, confidence interval 1.144–2.137, p < 0.001) (Supplementary Table 2).

Table 3.

A Generalized Estimating Equation (GEE) model to investigate the differences in NLR between FEP patients and healthy control with BDI-II scores, BAI scores, occupation, and years of education adjusted.

Model Constant β SE-β 95% CI of β p value
NLR 1.477
Group: FEP case group (reference: control group) 1.886 0.413 1.076 to 2.695 * < 0.001
Occupation − 0.289 0.399 − 1.071 to 0.494 0.47
Years of Education 0.022 0.046 − 0.068 to 0.111 0.634
BDI-II − 0.035 0.021 − 0.076 to 0.007 0.103
BAI 0.025 0.014 − 0.002 to 0.052 0.066

Outcome: NLR.

β, beta-coefficient; CI, confidence interval; SE, standard error; BDI-II, Beck Depression Inventory-II; BAI, Beck Anxiety Inventory.

*denotes p < 0.05.

Significant values are in bold.

Relationships of NLR with clinical and cognitive variables in FEP

In the correlation analyses, the NLR was found to be positively associated with PANSS-positive symptom score (ρ = 0.613, p < 0.001), PANSS-disorganization score (ρ = 0.566, p = 0.002), PANSS-excitation score (ρ = 0.628, p < 0.001) as well as PANSS-anxiety and depressive symptom score (ρ = 0.435, p = 0.023). It did not have a statistically significant correlation with the PANSS-negative symptom score (ρ = 0.272, p = 0.17). The NLR was also found to be positively associated with the CGI-S score (ρ = 0.644, p < 0.001) (Table 4). Further comparisons were made on the NLR of patients grouped by duration of untreated psychosis (DUP). No significant correlation was found in the NLR of FEP patients with their DUP (ρ = − 0.296, p = 0.134) (Table 4).

Table 4.

The correlation analyses between NLR and clinical symptoms, onset profile as well as the CANTAB neurocognitive test results in FEP patients.

Variables of interest Spearman's rho (ρ) p-value
Clinical symptoms
 PANSS-positive symptom score b 0.613 * < 0.001
 PANSS-disorganization score b 0.566 *0.002
 PANSS-negative symptom score b 0.272 *0.17
 PANSS-excitation score b 0.628 * < 0.001
PANSS-anxiety and depressive symptom score b 0.435 *0.023
 CGI-S score 0.644 * < 0.001
Onset profile
 Log DUPa − 0.296 0.134
Neurocognitive tests
 Verbal memory
 VRM-FR 0.063 0.755
 VRM-IR − 0.156 0.438
 VRM-DR − 0.139 0.49
Executive function
 SWM-BE 0.145 0.471
 SWE-S − 0.035 0.861
 OTS-PSFC − 0.188 0.348
 OTS-MLC 0.066 0.744

aDUP was log-transformed for parametric analysis due to its skewed distribution.

bPANSS positive, disorganization, negative, excitation, anxiety and depressive symptom scores were derived on the basis of a previous factor-analytic study on FEP patients35.

PANSS, Positive and Negative Syndrome Scale; CGI-S, Clinical Global Impression-Severity; DUP, duration of untreated psychosis; VRM, Verbal recognition memory test, -FR, free recall, -IR, immediate recognition, -DR, delayed recognition; SWM, Spatial working memory test, -BE, between errors, -S, strategy; OTS, One-touch stockings of Cambridge test, -PSFC, Number of problems solved on first choice, -MLC, median latency to first choice.

*Denotes p < 0.05.

Significant values are in bold.

Performances in all three components of VRM, including free recall (VRM-FR) (ρ = 0.063, p = 0.755), immediate recognition (VRM-IR) (ρ = − 0.156, p = 0.438), and delayed recognition (VRM-DR) (ρ = − 0.139, p = 0.49) were not correlated with the NLR. The performances in SWM-BE (ρ = 0.145, p = 0.471) and SWM-S (ρ = − 0.035, p = 0.861) were not correlated with the NLR. For the OTS, no significant correlations were found between the performances in both OTS-PFSC (ρ = − 0.188, p = 0.348) and OTS-MLC (ρ = 0.066, p = 0.744) with the NLR in the FEP patients (Table 4). No significant correlations were found when correlation analyses were performed between DUP and the scores on the CANTAB sub-tests. (Data not shown).

Discussion

Our study is the first to report the clinical correlations of NLR in non-affective FEP presenting to a tertiary care setting in Hong Kong SAR, and was among the few clinical studies that examined the clinical correlations of NLR in psychosis with the inclusion of ethnic Chinese. NLR was significantly higher in non-affective FEP patients than in age-/sex-matched healthy controls after accounting for the emotional state, education, and employment status. Our findings were consistent with the results reported in the meta-analysis, which reported an increased NLR of 0.65 in a pooled sample of relapsed patients with schizophrenia than in healthy controls, and an increased NLR of 0.52 in the pooled FEP subgroup patients than in healthy controls25. A higher total white cell count and neutrophil count but a lower lymphocyte count were observed in the FEP patients in our study. It is worth noting that lymphocyte count comparisons varied across different studies31,4244, and the mixed findings might reflect the complex relationships between lymphocyte level and clinical status, such as symptom severity, illness chronicity, and treatment status, as shown in an earlier meta-analysis45. An increase in neutrophil counts and a decrease in lymphocyte counts in other diseases might reflect an overall enhanced inflammatory intensity and an impaired immune system, respectively46. A possible underlying mechanistic cellular-based involvement in the predisposition to inflammatory states has been fueled but a recent study which reported an increased blood neutrophil extracellular traps (NETs) in patients with early schizophrenia compared with controls irrespective of antipsychotic treatment. An early stress with history of childhood maltreatment also linked to patients with increased NETs47.

Regarding the possible effect of drug treatment on NLR, other reports demonstrated years of antipsychotic treatment could reduce NLR26. The correlations between NLR and the different psychotic symptom severity could be altered by antipsychotic treatment27. Nonetheless, we still found a significantly higher NLR of the drug-naïve FEP patients than the healthy controls after excluding the three FEP subjects with prior antipsychotic treatment.

Existing literature often overlooked the confounding effects of the prevailing emotional state on inflammatory status. For instance, anxiety-related states48 or sadness49 might influence inflammatory status. The FEP patients in this study had more intense depressive and anxious states as measured with BDI-II and BAI, probably secondary to the underlying active psychotic symptoms and other social stressors. Interestingly, some published studies alluded to the effects of socioeconomic status, including education and income on inflammatory states, although there has not been any report on their direct association with NLR50,51. The correlations between the occupation status or years of education with BDI-II or BAI scores found no significant correlations (data not shown), with the variance inflation factor computed with either BDI-II or BAI scores toward occupation status and years of education to be 1.13, suggesting a low chance of multicollinearity between the variables in our data. Using a GEE model, a higher NLR in the FEP patients remained statistically significant when the emotional states, years of education, and occupation status were accounted for, implicating an independent association of higher NLR with FEP in an active psychotic state.

A higher NLR might allude to unfavorable prognosis in various medical conditions21,22,5254. Some evidence suggests that inflammation is associated with the risk of suicide, at least in adolescents55. Some recent evidence supported the association of higher NLR with the severity of psychotic state in patients with schizophrenia26,27. Amongst the non-affective FEP patients (schizophrenia spectrum disorder) in this case–control study, we found positive correlations between symptoms severity (reflected by the PANSS factors, as well as the CGI-S) with higher NLR, but no significant correlations between NLR and the duration of untreated psychosis (DUP). Our study revealed no significant correlation between NLR and PANSS-negative symptom score, parallel to findings reported in the existing review56. Overall it suggested the potential role of NLR as a biomarker of clinical severity in the acute episode of FEP patients.

Some animal studies have reported an association of increased inflammation with cognitive impairment57, while clinical studies have reported transdiagnostic associations of higher NLR with cognitive impairment in different psychiatric patients, including older adults5862. Our study did not find a significant correlation between NLR and the selected tests on executive function and working memory in FEP patients. Intriguingly, the positive association between higher NLR and cognitive impairment was not merely neurotoxic. Some components of inflammatory cytokines could exert neuroprotective effects in maintaining certain cognitive performances63. Social stressors, which inevitably affect the hypothalamic-pituitary hormonal axis, have been implicated in impairing cognitive functions in FEP patients64,65. Considering the varying stress level that was not quantified in this study and the complex interplay of inflammatory status and cognitive performance, NLR on its own is not a sensitive marker to predict the level of cognitive performance during the active psychotic states in patients with FEP who had a relatively short duration of untreated psychosis.

We considered the possibility of other associative factors, including the DUP, that have not been examined in previous studies. While the association of long DUP with cognitive impairment is generally accepted in chronic schizophrenia66, a recent meta-analysis concluded the DUP among FEP was not significantly related to the performances of most cognitive domains67. We also reported that our FEP patients across different DUPs performed similarly and had no statistically significant correlations in all the tested cognitive performances. Given the small sample size in this case–control study design, it might remain a caveat in interpretation that these sub-group analyses might not reflect a true null association of NLR with DUP.

The pre-requisite for applying NLR into clinical practice is defining the normative values of age-/ gender-/ethnic-specific NLR in a healthy population. An earlier study suggested the mean normal NLR in a healthy adult population was 1.6568, comparable to our present study showing a median NLR of 1.78 in the healthy controls. A more recent investigation that retrieved data from a routine examination center in Western China suggested a reference NLR could be 0.88 to 4.0 in a healthy ethnic Chinese Han population69. However, these studies offered limited information on the normative value of NLR, which is known to vary with age 70 and ethnicity24.

Our study's findings have to be interpreted by considering the methodological limitations. Biased sex distribution (18 females and 9 males) could be a potential bias, yet our control samples were sex- and age-matched with the FEP participants. Other published data also revealed no sex differences in NLR27. Rather than using a convenience sample for controls, healthy household family members of the FEP subjects could be recruited to optimize the matching of cases and controls as they might share closer environment such as diet. Aside, this case–control study did not measure and account for potential confounding factors such as differences in circadian rhythm in subjects across different seasons. Such uncontrolled confounder might possibly be remedied by measuring blood morning cortisol level, which is often unavailable in daily clinical settings. The inevitably stringent selection criteria has thus resulted in the small sample size, compromising the power of subgroup analyses and the generalizability of the observed results. In this regard, further studies by adding comparisons with FEP patients having affective symptoms might serve to offer valuable information not only to increase sample size, but also allowing subgroup analysis between patients with and without affective symptoms. It would also be of interest to include other possible psychiatric co-morbidities in FEP patients to assess their possible interactive or additive effects on NLR, given the transdiagnostic associations of NLR.

The observations in the present study offered preliminary evidence in Hong Kong Chinese that NLR might be used to guide the assessment of acute exacerbation in non-affective FEP patients. Such clinical utility is especially promising when symptom reporting might be hampered by a lack of insight and often unsatisfactory therapeutic alliance in psychiatric care settings. Future studies should prospectively examine the NLR changes and clinical correlates in a broader spectrum of patients (in terms of chronicity and severity of illness) to elucidate the potential prognostic utility of NLR.

Supplementary Information

Supplementary Tables. (20.2KB, docx)

Acknowledgements

We would like to thank Dr. Anne Choy and Dr. Kenneth Wong for their valuable advice and all the patients and healthy volunteers who contributed to the current study. We declare that there was no funding for the current study.

Author contributions

S.M.S.C.: Conception and design, provision of study material or patients, data analysis and interpretation, manuscript writing, final approval of manuscript; K.K.L.: Conception and design, administrative support, collection and/or assembly of data, data analysis and interpretation, manuscript writing; Y.C.W.: Conception and design, administrative support, manuscript writing; K.S.S.: Data analysis and interpretation, manuscript writing; S.C.C.: Data analysis and interpretation, manuscript writing; W.C.C.: Data analysis and interpretation, manuscript writing; Y.M.F.M.: Provision of study material or patients, administrative support. All authors reviewed the manuscript.

Data availability

The data generated and used for this study are available from the corresponding author upon reasonable request, and may be requested via email, schan@cuhk.edu.hk.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-023-37846-y.

References

  • 1.Felger JC. Imaging the role of inflammation in mood and anxiety-related disorders. Curr. Neuropharmacol. 2018;16(5):533–558. doi: 10.2174/1570159X15666171123201142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Khandaker GM, et al. Inflammation and immunity in Schizophrenia: Implications for pathophysiology and treatment. Lancet Psychiatry. 2015;2(3):258–270. doi: 10.1016/S2215-0366(14)00122-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Müller N. Inflammation in Schizophrenia: Pathogenetic aspects and therapeutic considerations. Schizophr. Bull. 2018;44(5):973–982. doi: 10.1093/schbul/sby024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Kroken RA, Sommer IE, Steen VM, Dieset I, Johnsen E. Constructing the immune signature of Schizophrenia for clinical use and research; An integrative review translating descriptives into diagnostics. Front. Psychiatry. 2019;9:753. doi: 10.3389/fpsyt.2018.00753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Hong J, Bang M. Anti-inflammatory Strategies for Schizophrenia: A review of evidence for therapeutic applications and drug repurposing. Clin. Psychopharmacol. Neurosci. 2020;18(1):10–24. doi: 10.9758/cpn.2020.18.1.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: Comparisons between Schizophrenia, bipolar disorder and depression. Mol. Psychiatry. 2016;21(12):1696–1709. doi: 10.1038/mp.2016.3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Kulaksizoglu B, Kulaksizoglu S. Relationship between neutrophil/lymphocyte ratio with oxidative stress and psychopathology in patients with Schizophrenia. Neuropsychiatr. Dis. Treat. 2016;12:1999–2005. doi: 10.2147/NDT.S110484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Garcia-Rizo C, et al. Blood cell count in antipsychotic-naive patients with non-affective psychosis. Early Interv. Psychiatry. 2019;13(1):95–100. doi: 10.1111/eip.12456. [DOI] [PubMed] [Google Scholar]
  • 9.Steiner J, et al. Innate immune cells and C-reactive protein in acute first-episode psychosis and schizophrenia: Relationship to psychopathology and treatment. Schizophr. Bull. 2020;46(2):363–373. doi: 10.1093/schbul/sbz068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Rodrigues-Amorim D, et al. Cytokines dysregulation in Schizophrenia: A systematic review of psychoneuroimmune relationship. Schizophr Res. 2018;197:19–33. doi: 10.1016/j.schres.2017.11.023. [DOI] [PubMed] [Google Scholar]
  • 11.Bolu A, et al. Serum levels of high sensitivity C-reactive protein in drug-naïve first-episode psychosis and acute exacerbation of Schizophrenia. Clin. Psychopharmacol. Neurosci. 2019;17(2):244–249. doi: 10.9758/cpn.2019.17.2.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Fraguas D, et al. Oxidative stress and inflammation in first-episode psychosis: A systematic review and meta-analysis. Schizophr. Bull. 2019;45(4):742–751. doi: 10.1093/schbul/sby125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Baumeister D, Ciufolini S, Mondelli V. Effects of psychotropic drugs on inflammation: Consequence or mediator of therapeutic effects in psychiatric treatment? Psychopharmacology. 2016;233(9):1575–1589. doi: 10.1007/s00213-015-4044-5. [DOI] [PubMed] [Google Scholar]
  • 14.Martinuzzi E, et al. Stratification and prediction of remission in first-episode psychosis patients: The OPTiMiSE cohort study. Transl. Psychiatry. 2019;9(1):20. doi: 10.1038/s41398-018-0366-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Mondelli V, et al. Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophr. Bull. 2015;41(5):1162–1170. doi: 10.1093/schbul/sbv028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Ribeiro-Santos A, Teixeira AL, Salgado JV. Evidence for an immune role on cognition in Schizophrenia: A systematic review. Curr. Neuropharmacol. 2014;12(3):273–280. doi: 10.2174/1570159X1203140511160832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Bora E. Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in Schizophrenia: A meta-analysis. Psychol. Med. 2019;49(12):1971–1979. doi: 10.1017/S0033291719001685. [DOI] [PubMed] [Google Scholar]
  • 18.Cabrera B, et al. Cognition and psychopathology in first-episode psychosis: Are they related to inflammation? Psychol. Med. 2016;46(10):2133–2144. doi: 10.1017/S0033291716000659. [DOI] [PubMed] [Google Scholar]
  • 19.Buonacera A, et al. Neutrophil to lymphocyte ratio: An emerging marker of the relationships between the immune system and diseases. Int. J. Mol. Sci. 2022;23(7):3636. doi: 10.3390/ijms23073636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Howard R, Kanetsky PA, Egan KM. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Sci. Rep. 2019;9(1):19673. doi: 10.1038/s41598-019-56218-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Liu CC, et al. Neutrophil-to-lymphocyte ratio as a predictive marker of metabolic syndrome. Medicine (Baltimore) 2019;98(43):e17537. doi: 10.1097/MD.0000000000017537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Huang Z, Fu Z, Huang W, Huang K. Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: A meta-analysis. Am. J. Emerg. Med. 2020;38(3):641–647. doi: 10.1016/j.ajem.2019.10.023. [DOI] [PubMed] [Google Scholar]
  • 23.Okba AM, et al. Neutrophil/lymphocyte ratio and lymphocyte/monocyte ratio in ulcerative colitis as non-invasive biomarkers of disease activity and severity. Auto Immun. Highlights. 2019;10(1):4. doi: 10.1186/s13317-019-0114-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Brinn A, Stone J. Neutrophil-lymphocyte ratio across psychiatric diagnoses: A cross-sectional study using electronic health records. BMJ Open. 2020;10(7):e036859. doi: 10.1136/bmjopen-2020-036859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Karageorgiou V, Milas GP, Michopoulos I. Neutrophil-to-lymphocyte ratio in Schizophrenia: A systematic review and meta-analysis. Schizophr. Res. 2019;206:4–12. doi: 10.1016/j.schres.2018.12.017. [DOI] [PubMed] [Google Scholar]
  • 26.Kovács MÁ, et al. Elevated osteopontin and interferon gamma serum levels and increased neutrophil-to-lymphocyte ratio are associated with the severity of symptoms in Schizophrenia. Front. Psychiatry. 2020;10:996. doi: 10.3389/fpsyt.2019.00996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Zhou X, et al. Neutrophil-to-lymphocyte ratio is independently associated with severe psychopathology in schizophrenia and is changed by antipsychotic administration: A large-scale cross-sectional retrospective study. Front. Psychiatry. 2020;11:581061. doi: 10.3389/fpsyt.2020.581061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Viktoriya M. The interplay between stress, inflammation, and emotional attention: Relevance for depression. Front. Neurosci. 2019;13:384. doi: 10.3389/fnins.2019.00384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Mazza MG, et al. Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in mood disorders: A meta-analysis. Prog Neuropsychopharmacol. Biol. Psychiatry. 2018;84(Pt A):229–236. doi: 10.1016/j.pnpbp.2018.03.012. [DOI] [PubMed] [Google Scholar]
  • 30.Mondelli V, Howes O. Inflammation: Its role in Schizophrenia and the potential anti-inflammatory effects of antipsychotics. Psychopharmacology. 2014;231(2):317–318. doi: 10.1007/s00213-013-3383-3. [DOI] [PubMed] [Google Scholar]
  • 31.Moody G, Miller BJ. Total and differential white blood cell counts and hemodynamic parameters in first-episode psychosis. Psychiatry Res. 2018;260:307–312. doi: 10.1016/j.psychres.2017.11.086. [DOI] [PubMed] [Google Scholar]
  • 32.So E, et al. The Chinese-bilingual SCID-I/P project: Stage 1-reliability for mood disorders and Schizophrenia. Hong Kong J. Psychiatry. 2003;13(1):7. [Google Scholar]
  • 33.Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for Schizophrenia. Schizophr. Bull. 1987;13(2):261–276. doi: 10.1093/schbul/13.2.261. [DOI] [PubMed] [Google Scholar]
  • 34.Kay SR, Opler LA, Fiszbein A. The Structured Clinical Interview for Positive and Negative Syndromes of Schizophrenia. Multi-Health Systems; 1992. [Google Scholar]
  • 35.Emsley R., Rabinowitz J., Torreman M., RIS-INT-35 Early Psychosis Global Working Group The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophr. Res. 2003;61(1):47–57. doi: 10.1016/S0920-9964(02)00302-X. [DOI] [PubMed] [Google Scholar]
  • 36.Leung KW. A validation of the Traditional Chinese (Hong Kong) Versions of the Beck Anxiety Inventory (BAI) and the Beck Depression Inventory-II(BDI-II) The University of Hong Kong; 2001. [Google Scholar]
  • 37.CANTAB® [cognitive assessment software]. Retrieved from Cambridge Cognition:www.cantab.com (2019).
  • 38.Aas M, et al. A systematic review of cognitive function in first-episode psychosis includes discussing childhood trauma, stress, and inflammation. Front. Psychiatry. 2014;4:182. doi: 10.3389/fpsyt.2013.00182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Busner J, Targum SD. The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry (Edgmont) 2007;4(7):28–37. [PMC free article] [PubMed] [Google Scholar]
  • 40.Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2. Lawrence Erlbaum Associates, Publishers; 1998. [Google Scholar]
  • 41.Furuncuoğlu Y, et al. How obesity affects the neutrophil/lymphocyte and platelet/lymphocyte ratio, systemic immune-inflammatory index and platelet indices: A retrospective study. Eur. Rev. Med. Pharmacol. Sci. 2016;20(7):1300–1306. [PubMed] [Google Scholar]
  • 42.Varsak N, Aydin M, Eren I. The evaluation of neutrophil-lymphocyte ratio in patients with first episode psychosis. Fam. Pract. Palliat. Care. 2016;1(3):65–69. doi: 10.22391/920.287411. [DOI] [Google Scholar]
  • 43.Yüksel RN, Ertek IE, Dikmen AU, Göka E. High neutrophil-lymphocyte ratio in Schizophrenia independent of infectious and metabolic parameters. Nord. J. Psychiatry. 2018;72(5):336–340. doi: 10.1080/08039488.2018.1458899. [DOI] [PubMed] [Google Scholar]
  • 44.Rodríguez JFO, Fernández JD, Mira NO, López-Briz E, Gómez-Pajares F. Neutrophil/lymphocyte ratio: Can a non-specific marker of inflammation helps to confirm the inflammatory hypothesis of the serious mental diseases? A case-control study. Med. Hypotheses. 2019;130:109279. doi: 10.1016/j.mehy.2019.109279. [DOI] [PubMed] [Google Scholar]
  • 45.Miller BJ, Gassama B, Sebastian D, Buckley P, Mellor A. Meta-analysis of lymphocytes in Schizophrenia: Clinical status and antipsychotic effects. Biol. Psychiatry. 2013;73(10):993–999. doi: 10.1016/j.biopsych.2012.09.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Zhu Z, et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int. J. Infect. Dis. 2020;95:332–339. doi: 10.1016/j.ijid.2020.04.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Corsi-Zuelli F, et al. Increased blood neutrophil extracellular traps (NETs) associated with early life stress: Translational findings in recent-onset schizophrenia and rodent model. Transl. Psychiatry. 2022;12(1):526. doi: 10.1038/s41398-022-02291-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Michopoulos V, Powers A, Gillespie CF, Ressler KJ, Jovanovic T. Inflammation in fear- and anxiety-based Disorders: PTSD, GAD, and beyond. Neuropsychopharmacology. 2017;42(1):254–270. doi: 10.1038/npp.2016.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Fagundes CP, et al. Grief, depressive symptoms, and inflammation in the spousally bereaved. Psychoneuroendocrinology. 2019;100:190–197. doi: 10.1016/j.psyneuen.2018.10.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Steinvil A, et al. Relation of educational level to inflammation-sensitive biomarker level. Am. J. Cardiol. 2008;102(8):1034–1039. doi: 10.1016/j.amjcard.2008.05.055. [DOI] [PubMed] [Google Scholar]
  • 51.Friedman EM, Herd P. Income, education, and inflammation: differential associations in a national probability sample (The MIDUS Study) Psychosom. Med. 2010;72(3):290–300. doi: 10.1097/PSY.0b013e3181cfe4c2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Peng Y, et al. The role of neutrophil to lymphocyte ratio for the assessment of liver fibrosis and cirrhosis: A systematic review. Expert Rev. Gastroenterol. Hepatol. 2018;12(5):503–513. doi: 10.1080/17474124.2018.1463158. [DOI] [PubMed] [Google Scholar]
  • 53.Cupp MA, et al. Neutrophil to lymphocyte ratio and cancer prognosis: An umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020;18(1):360. doi: 10.1186/s12916-020-01817-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Yang Y, Xu Y, Wang J, Zhai X, Jiang H. Predictive efficacy of neutrophil-to-lymphocyte ratio for long-term prognosis in new onset acute coronary syndrome: A retrospective cohort study. BMC Cardiovasc. Disord. 2020;20(1):500. doi: 10.1186/s12872-020-01773-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Ucuz İ, Tetik BK. Can suicide behavior and seasonality of suicide be predicted from inflammatory parameters in adolescents? Med. Hypotheses. 2020;143:110061. doi: 10.1016/j.mehy.2020.110061. [DOI] [PubMed] [Google Scholar]
  • 56.Sandberg AA, Steen VM, Torsvik A. Is elevated neutrophil count and neutrophil-to-lymphocyte ratio a cause or consequence of schizophrenia?-A scoping review. Front. Psychiatry. 2021;12:728990. doi: 10.3389/fpsyt.2021.728990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Cunningham C, et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol. Psychiatry. 2009;65(4):304–312. doi: 10.1016/j.biopsych.2008.07.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Hope S, et al. Inflammatory markers are associated with general cognitive abilities in schizophrenia and bipolar disorder patients and healthy controls. Schizophr. Res. 2015;165(2–3):188–194. doi: 10.1016/j.schres.2015.04.004. [DOI] [PubMed] [Google Scholar]
  • 59.Aykut DS, Arslan FC, Karagüzel EÖ, Aral G, Karakullukçu S. The relationship between neutrophil-lymphocyte, platelet-lymphocyte ratio and cognitive functions in bipolar disorder. Nord. J. Psychiatry. 2018;72(2):119–123. doi: 10.1080/08039488.2017.1397192. [DOI] [PubMed] [Google Scholar]
  • 60.An P, et al. Association of neutrophil-lymphocyte ratio with mild cognitive impairment in elderly Chinese adults: A case-control study. Curr. Alzheimer Res. 2019;16(14):1309–1315. doi: 10.2174/1567205017666200103110521. [DOI] [PubMed] [Google Scholar]
  • 61.Sayed A, et al. The neutrophil-to-lymphocyte ratio in Alzheimer's disease: Current understanding and potential applications. J. Neuroimmunol. 2020;349:577398. doi: 10.1016/j.jneuroim.2020.577398. [DOI] [PubMed] [Google Scholar]
  • 62.Liu JH, et al. Elevated blood neutrophil to lymphocyte ratio in older adults with cognitive impairment. Arch. Gerontol. Geriatr. 2020;88:104041. doi: 10.1016/j.archger.2020.104041. [DOI] [PubMed] [Google Scholar]
  • 63.Zhang XY, et al. Interleukin 18 and cognitive impairment in first-episode and drug naïve schizophrenia versus healthy controls. Brain Behav. Immun. 2013;32:105–111. doi: 10.1016/j.bbi.2013.03.001. [DOI] [PubMed] [Google Scholar]
  • 64.Aas M, et al. Abnormal cortisol awakening response predicts worse cognitive function in patients with first-episode psychosis. Psychol. Med. 2011;41(3):463–476. doi: 10.1017/S0033291710001170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Labad J, et al. Free thyroxine levels are associated with cognitive changes in individuals with a first episode of psychosis: A prospective 1-year follow-up study. Schizophr. Res. 2016;171(1–3):182–186. doi: 10.1016/j.schres.2016.01.036. [DOI] [PubMed] [Google Scholar]
  • 66.Stone WS, et al. Association between the duration of untreated psychosis and selective cognitive performance in community-dwelling individuals with chronic untreated schizophrenia in rural China. JAMA Psychiatry. 2020;77(11):1116–1126. doi: 10.1001/jamapsychiatry.2020.1619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Bora E, Yalincetin B, Akdede BB, Alptekin K. Duration of untreated psychosis and neurocognition in first-episode psychosis: A meta-analysis. Schizophr. Res. 2018;193:3–10. doi: 10.1016/j.schres.2017.06.021. [DOI] [PubMed] [Google Scholar]
  • 68.Forget P, et al. What is the normal value of the neutrophil-to-lymphocyte ratio? BMC Res. Notes. 2017;10(1):12. doi: 10.1186/s13104-016-2335-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Luo H, et al. Normal reference intervals of neutrophil -to- lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and systemic immune inflammation index in healthy adults: A large multi-center study from western China. Clin. Lab. 2019;65(3):180715. doi: 10.7754/Clin.Lab.2018.180715. [DOI] [PubMed] [Google Scholar]
  • 70.Li J, et al. Neutrophil-to-lymphocyte ratio positively correlates to age in healthy population. J. Clin. Lab. Anal. 2015;29(6):437–443. doi: 10.1002/jcla.21791. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Tables. (20.2KB, docx)

Data Availability Statement

The data generated and used for this study are available from the corresponding author upon reasonable request, and may be requested via email, schan@cuhk.edu.hk.


Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES